期刊文献+

胆囊癌的靶向治疗进展 被引量:7

Development of targeted therapy for gallbladder carcinoma
原文传递
导出
摘要 胆囊癌(gallbladder carcinoma,GBC)是胆道系统最常见的恶性肿瘤,每年全球发病率是2.2/10万人,死亡率是1.7/10万人。手术是治疗胆囊癌唯一有效方法,但胆囊癌早期无特异性症状,临床诊断时大多为中晚期患者,往往已失去手术机会,而胆囊癌对放化疗相对不敏感,近年来总体预后较差。近年来分子靶向治疗进展突飞猛进,具有特异性强、副作用小、耐药较少等优点。本文就胆囊癌发生、发展过程中相关基因的表达异常、涉及的信号通路及潜在治疗靶点作一综述。
出处 《中华肝脏外科手术学电子杂志》 CAS 2018年第3期244-247,共4页 Chinese Journal of Hepatic Surgery(Electronic Edition)
基金 上海市卫计委课题(201640208)
  • 相关文献

参考文献4

二级参考文献72

  • 1何振平.胆囊癌的临床特征及外科治疗[J].现代医药卫生,2004,20(18):1829-1830. 被引量:3
  • 2Ooi A,Kobayashi M,Mai M,Nakanishi I.Amplification of c-erbB-2 in gastric cancer:detection in formalinfixed,paraffin-embedded tissue by fluorescence in situ hybridization.Lab Invest 1998; 78:345-351.
  • 3Takehana T,Kunitomo K,Suzuki S,Kono K,Fujii H,Matsumoto Y,Ooi A.Expression of epidermal growth factor receptor in gastric carcinomas.Clin Gastroenterol Hepatol 2003; 1:438-445.
  • 4Ito Y,Takeda T,Sasaki Y,Sakon M,Yamada T,Ishiguro S,Imaoka S,Tsujimoto M,Higashiyama S,Monden M,Matsuura N.Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma.Pathol Res Pract 2001; 197:95-100.
  • 5Yoshikawa D,Ojima H,Iwasaki M,Hiraoka N,Kosuge T,Kasai S,Hirohashi S,Shibata T.Clinicopathological and prognostic significance of EGFR,VEGF,and HER2 expression in cholangiocarcinoma.Br J Cancer 2008; 98:418-425.
  • 6Nehls O,Oettle H,Hartmann JT,Hofheinz RD,Hass HG,Horger MS,Koppenh(o)fer U,Hochhaus A,Stieler J,Trojan J,Gregor M,Klump B.Capecitabine plus oxaliplatin as firstline treatment in patients with advanced biliary system adenocarcinoma:a prospective multicentre phase II trial.Br J Cancer 2008; 98:309-315.
  • 7Harder J,Riecken B,Kummer O,Lohrmann C,Otto F,Usadel H,Geissler M,Opitz O,Henss H.Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer.Br J Cancer 2006; 95:848-852.
  • 8Voravud N,Foster CS,Gilbertson JA,Sikora K,Waxman J.Oncogene expression in cholangiocarcinoma and in normal hepatic development.Hum Pathol 1989; 20:1163-1168.
  • 9Yau TK,Sze H,Soong IS,Hioe F,Khoo US,Lee AW.HER2 overexpression of breast cancers in Hong Kong:prevalence and concordance between immunohistochemistry and insitu hybridisation assays.Hong Kong Med J 2008; 14:130-135.
  • 10Carlson RW,Moench SJ,Hammond ME,Perez EA,Burstein HJ,Allred DC,Vogel CL,Goldstein LJ,Somlo G,Gradishar WJ,Hudis CA,Jahanzeb M,Stark A,Wolff AC,Press MF,Winer EP,Paik S,Ljung BM.HER2 testing in breast cancer:NCCN Task Force report and recommendations.J Natl Compr Canc Netw 2006; 4 Suppl 3:S1-S22; quiz S23-S24.

共引文献56

同被引文献81

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部